ABVC BioPharma Inc (NASDAQ:ABVC)’s traded shares stood at 0.66 million during the last session, with the company’s beta value hitting 0.24. At the close of trading, the stock’s price was $3.11, to imply an increase of 0.32% or $0.01 in intraday trading. The ABVC share’s 52-week high remains $3.10, putting it 0.32% up since that peak but still an impressive 87.14% since price per share fell to its 52-week low of $0.40. The company has a valuation of $52.81M, with an average of 0.54 million shares in intraday trading volume over the past 10 days and average of 414.55K shares over the past 3 months.
Analysts have given a consensus recommendation of Hold for ABVC BioPharma Inc (ABVC), translating to a mean rating of 3.00. Of 1 analyst(s) looking at the stock, 0 analyst(s) give ABVC a Sell rating. 0 of those analysts rate the stock as Overweight while 1 advise Hold as 0 recommend it as a Buy.
ABVC BioPharma Inc (NASDAQ:ABVC) trade information
After registering a 0.32% upside in the last session, ABVC BioPharma Inc (ABVC) has traded red over the past five days. The 5-day price performance for the stock is 42.01%, and 88.48% over 30 days. With these gigs, the year-to-date price performance is 279.31%. Short interest in ABVC BioPharma Inc (NASDAQ:ABVC) saw shorts transact 0.51 million shares and set a 1.48 days time to cover.
ABVC Dividends
ABVC BioPharma Inc has its next earnings report out on 2023-May-15. However, it is important to take into account that this dividend yield ratio is just an indicator to only serve the purpose of guidance. Investors interested to invest in the stock should ponder company’s other fundamental and operations related aspects too.
ABVC BioPharma Inc (NASDAQ:ABVC)’s Major holders
ABVC BioPharma Inc insiders hold 16.47% of total outstanding shares, with institutional holders owning 2.28% of the shares at 2.73% float percentage. In total, 2.28% institutions holds shares in the company.
